ODTX News
Archived Headlines
- US IPO Week Ahead: Cement carve-out leads the IPO calendar as more gear up to launch 01/31/25
- Sizable IPO filings reach a three-year high amid steady stream of deals 01/30/25
- US IPO Weekly Recap: Oil and gas well equipment provider Flowco debuts, while more sizable deals join the pipeline 01/17/25
- Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO 01/17/25
Autoimmune biotech Odyssey Therapeutics withdraws $100 million IPO
Odyssey Therapeutics, a Phase 2-ready biotech developing precision therapies for autoimmune diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2025 with a proposed deal size of $100 million. Focused on...read more
US IPO Week Ahead: Small IPOs may list amid market volatility
...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially. ...read more
US IPO Week Ahead: IPO market set to end February on a quiet note
Updated Monday, 2/24. While the calendar looks quiet for the week ahead, some small deals may join late. Singapore healthcare practice Basel Medical (BMGL) is tentatively scheduled to raise $10 million at an $83 million market cap. Through its two...read more